Last Updated: September 24, 2026

Details for New Drug Application (NDA): 021883

✉ Email this page to a colleague

NDA 021883 describes DALVANCE, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the DALVANCE profile page.

The generic ingredient in DALVANCE is dalbavancin hydrochloride. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the dalbavancin hydrochloride profile page.

Summary for 021883

Tradename:	DALVANCE
Applicant:	Abbvie
Ingredient:	dalbavancin hydrochloride
Patents:	1

Pharmacology for NDA: 021883

Suppliers and Packaging for NDA: 021883

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DALVANCE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	021883	NDA	Allergan, Inc.	57970-100	57970-100-01	1 VIAL in 1 PACKAGE (57970-100-01) / 25 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INTRAVENOUS			Strength	EQ 500MG BASE/VIAL
Approval Date:	May 23, 2014	TE:	AP	RLD:	Yes
Patent:	6,900,175	Patent Expiration:	May 23, 2028	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) IN ADULT AND PEDIATRIC PATIENTS USING A TWO-DOSE REGIMEN OF DALBAVANCIN

Expired US Patents for NDA 021883

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	DALVANCE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	021883-001	May 23, 2014	7,115,564	⤷ Start Trial
Abbvie	DALVANCE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	021883-001	May 23, 2014	8,143,212	⤷ Start Trial
Abbvie	DALVANCE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	021883-001	May 23, 2014	7,119,061	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.